Industry News
Research partnership boost
The Minister of Education, Science and Training, Dr Brendan Nelson has announced that the Australian Government would provide more than A$60.4 million for research in the latest round of the Australian Research Council’s (ARC) Linkage Projects Scheme.
[ + ]Peplin gears up for skin drug trials
Brisbane's Peplin Biotech (ASX:PEP) has enrolled the last of 60 Australian patients for its Phase IIa clinical trial of its topical PEP005 treatment for actinic keratoses (AKs) -- pre-cancerous, dry, scaly areas of sun-damaged skin. [ + ]
CBio opens new labs, outlines development plans
Brisbane biopharma CBio has broken the proverbial bottle of champagne over the bows of its new laboratory and office premises at Brisbane Technology Park, and with Commonwealth P3 grant in hand, is ready to "forge ahead" with developing its novel anti-inflammatory molecule. [ + ]
In brief: Prima, SciGen, Sonic
The executive director of the Austin Research Institute, Mark Hogarth, has resigned as a director of Prima Biomed (ASX:PRR). The company cited Hogarth's increased responsibilities at the ARI for his resignation. [ + ]
Avexa back to the drawing board on hepatitis B program
Melbourne-based biotech Avexa (ASX:AVX) has been forced to rethink its plans to develop its reformulated hepatitis B candidate AVX491. [ + ]
Gene research facility opens at ANU
A $20 million national facility which will help the nation to remain at the cutting edge of gene research has been officially opened at The Australian National University.
[ + ]Progen hires Burrill as PI-88 heads to market
Brisbane cancer-drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) has appointed San Francisco's Burrill and Co as matchmaker to sift its crammed dance card for a partner to take its promising angiogenesis inhibitor PI-88 to the market. [ + ]
In brief: Acrux, Psiron, Circadian
Acrux (ASX:ACR) has received a US$1 million milestone payment from Vivus for its estradiol transdermal spray product Evamist, currently in Phase III clinical trials to treat menopausal symptoms in the US, which was due today. [ + ]
EvoGenix to list on ASX in August
Antibody therapeutics company EvoGenix will open its initial public offering within a week and list on the ASX in early to mid-August, with the aim of raising AUD$9 million. [ + ]
Research centres established
Bionic ears that connect directly to hearing nerves and provide near-normal hearing capability may soon become reality. Along with other research areas like renewable energy and sustainable industries, the advances to be achieved by the recently established Australian Centre of Electromaterials Science are expected to be particularly valuable to the manufacturing industry.
[ + ]Gates Foundation funds UQ dengue research
University of Queensland parasitologist Prof Scott O'Neill has won a prestigious grant from the Bill and Melinda Gates Foundation in the US to work on a remarkable symbiotic bacteria that induces sterility in insects. [ + ]
In brief: CSL, Progen Industries, Mayne Group
CSL (ASX:CSL) will be conducting a further on-market buyback of up to 8 million shares during a 12-month period commencing July 12. [ + ]
Brain pacemaker could ease severe depression - study
Patients suffering from severe depression who have not responded to other treatments may be helped by deep brain stimulation, researchers said. [ + ]
FDA approves first 'ethnic medicine'
The FDA, as expected, has followed the recommendation of an advisory panel last week and approved the heart drug BiDil, which clinical data have shown works well in African-Americans but poorly in other populations. [ + ]
Medical Developments share price boosted by Penthrox trial
Melbourne based Medical Developments International (ASX:MVP) believes the launch of its Penthrox Inhaler into the Australian dentistry market caused a share price rise from $0.745 on June 24, to $0.87 on June 27, prompting the ASX to issue the company with a 'speeding ticket'. [ + ]
